chronic
obstruct
pulmonari
diseas
copd
inflammatori
airway
disord
acut
exacerb
repres
major
complic
acut
exacerb
substanti
caus
morbid
mortal
prevent
exacerb
remain
major
unmet
need
increas
interest
recent
identifi
subgroup
patient
copd
risk
exacerb
defin
frequent
exacerb
phenotyp
patient
frequent
exacerb
wors
clinic
outcom
includ
increas
morbid
acceler
lung
function
declin
greater
mortal
suggest
group
requir
special
consider
date
underli
mechan
predispos
patient
frequent
exacerb
elucid
plausibl
abnorm
host
immun
could
underli
increas
propens
exacerb
virus
major
aetiolog
trigger
exacerb
data
exist
suggest
copd
may
associ
defici
antivir
immun
howev
studi
shown
abnorm
suggest
may
vari
accord
diseas
phenotyp
frequent
exacerb
could
repres
one
subgroup
defect
antivir
immun
promin
experiment
naturallyoccur
exacerb
studi
also
confirm
initi
viru
infect
precipit
secondari
bacteri
infect
copd
neutrophil
elastaseinduc
cleavag
antimicrobi
peptid
believ
import
mechanist
although
bacteri
colonis
stabl
state
shown
associ
increas
exacerb
frequenc
antimicrobi
peptid
respons
propens
develop
secondari
bacteri
infect
virusinfect
frequent
versu
infrequ
exacerb
previous
studi
hypothesis
patient
copd
histori
frequent
exacerb
would
impair
antivir
andor
antibacteri
immun
compar
infrequ
exacerb
use
analysi
sputum
sampl
cohort
patient
monitor
prospect
commun
combin
vitro
experi
bec
sampl
patient
copd
differenti
airliquid
interfac
ali
show
lung
innat
antimicrobi
immun
impair
frequent
exacerb
mechan
may
underli
increas
propens
exacerb
observ
patient
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
cohort
copd
subject
recruit
longitudin
studi
carri
st
mari
hospit
london
uk
june
decemb
investig
pathogenesi
naturallyoccur
copd
exacerb
studi
protocol
approv
east
london
research
ethic
committe
studi
number
subject
gave
inform
written
consent
subject
clinic
diagnosi
copd
confirm
spirometri
subject
initi
visit
baselin
clinic
stabl
clinic
assess
spirometri
forc
expiratori
volum
second
fev
forc
vital
capac
fvc
peak
expiratori
flow
pef
clinic
sampl
collect
includ
spontan
induc
sputum
taken
process
previous
describ
baselin
visit
subject
ask
number
exacerb
experienc
previou
year
group
two
group
frequent
exacerb
exacerb
preced
year
infrequ
exacerb
exacerb
previou
year
previous
describ
subject
repeat
visit
three
monthli
interv
clinic
stabl
follow
minimum
month
subject
report
studi
team
develop
symptom
upper
respiratori
tract
infect
increas
symptom
dyspnoea
cough
sputum
volum
purul
exacerb
defin
use
east
london
cohort
criteria
subject
seen
within
hour
onset
symptom
collect
sampl
repeat
visit
carri
two
week
initi
exacerb
visit
sampl
cohort
use
previou
studi
investig
role
airway
glucos
copd
baselin
analys
sputum
solubl
mediat
addit
sampl
taken
natur
occur
exacerb
studi
also
includ
baselin
preinfect
sampl
copd
subject
recruit
experiment
challeng
copd
studi
subject
studi
gave
inform
written
consent
protocol
approv
st
mari
nh
trust
research
ethic
committe
studi
number
subject
characteris
frequent
infrequ
exacerb
use
definit
describ
sputum
sampl
process
use
exactli
methodolog
describ
natur
occur
exacerb
studi
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
primari
bec
obtain
bronchoscop
patient
copd
gold
stage
ii
iii
grown
confluent
differenti
air
liquidinterfac
ali
previous
describ
subject
includ
gave
inform
written
consent
studi
protocol
approv
hunter
new
england
human
research
ethic
committe
primari
cell
grown
complet
bronchial
epitheli
cell
growth
medium
begm
lonza
growth
factor
supplement
submerg
monolay
cultur
seed
x
cellsml
transwel
confluent
infect
moi
appli
apic
surfac
hour
bronchial
epitheli
basal
medium
bebm
minim
c
follow
infect
media
replac
fresh
bebm
minim
remaind
experi
sampl
collect
hour
postinfect
apic
media
remov
store
protein
express
analys
type
iii
ifn
protein
measur
use
customdesign
legendplex
kit
biolegend
measur
use
verikin
elisa
pbl
half
transwel
membran
also
care
cut
insert
collect
rlt
buffer
qiagen
contain
downstream
molecular
analys
rtqpcr
remain
transwel
membran
fix
neutralbuff
formalin
hour
histolog
crosssect
confirm
differenti
protein
level
cellfre
sputum
sampl
measur
use
duoset
elisa
kit
r
system
accord
manufactur
instruct
protein
level
antimicrobi
peptid
assay
use
commerci
elisa
assay
kit
previous
describ
sourc
individu
elisa
follow
elafin
r
system
mannos
bind
lectin
mbl
r
system
slpi
r
system
total
rna
extract
sputum
cell
pellet
bronchial
epitheli
cell
lysat
store
rlt
buffer
rneasi
kit
qiagen
use
cdna
synthesi
omniscript
rt
kit
quantit
pcr
carri
use
previous
describ
specif
primer
probe
gene
interest
normal
rrna
reaction
analys
use
abi
fast
realtim
pcr
system
appli
biosystem
carlsbad
ca
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
dna
extract
total
sputum
perform
use
fastdna
spin
kit
soil
mp
biomed
santa
ana
usa
per
manufactur
instruct
beadbeat
perform
two
cycl
second
rpm
precelli
bertin
technolog
montignylebretonneux
franc
total
bacteri
load
measur
use
quantit
pcr
previous
describ
virus
detect
describ
previous
comparison
sputum
mrna
express
protein
concentr
frequent
infrequ
exacerb
analys
use
mannwhitney
u
test
vitro
experi
baselin
versu
rvinduc
express
analys
use
wilcoxon
ranksum
test
mann
whitney
u
test
use
compar
rv
induct
mrna
protein
frequent
infrequ
exacerb
correl
dataset
examin
use
spearman
rank
correl
coeffici
statist
perform
use
graphpad
prism
softwar
differ
consid
signific
p
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
utilis
communitybas
cohort
copd
patient
evalu
antimicrobi
immun
baselin
stablest
viru
associ
exacerb
baselin
analys
sputum
cell
mrna
interferon
ifn
interferonstimual
gene
isg
patient
suffici
sampl
evalu
patient
classifi
frequent
exacerb
clinic
characterist
shown
tabl
baselin
analys
sputum
solubl
mediat
mbl
slpi
elafin
protein
sampl
total
copd
patient
combin
commun
cohort
subject
recruit
experiment
infect
studi
avail
patient
classifi
frequent
exacerb
clinic
characterist
also
shown
tabl
sinc
virus
major
caus
exacerb
defici
antivir
immun
observ
studi
copd
hypothesis
frequent
exacerb
would
tabl
greater
heterogen
trend
increas
viral
load
observ
bec
frequent
exacerb
supplementari
fig
signific
induct
mrna
baselin
observ
frequent
infrequ
exacerb
hour
postinfect
figur
rv
induct
mrna
significantli
lower
frequent
versu
infrequ
exacerb
similar
trend
observ
mrna
signific
differ
observ
fig
rv
induct
isg
viperin
mrna
also
significantli
lower
frequent
versu
exacerb
signific
differ
observ
pkr
figur
collect
data
support
vivo
find
exacerb
patient
antivir
respons
reduc
frequent
exacerb
extend
observ
identifi
dysregul
innat
immun
respons
bec
defin
impair
express
ifn
isg
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
virusinduc
exacerb
trigger
subsequ
bacteri
infect
copd
secondari
phenomenon
associ
increas
exacerb
sever
invers
relat
interferon
respons
observ
antivir
immun
reduc
frequent
exacerb
vivo
primari
bec
patient
copd
vitro
next
examin
whether
sputum
bacteri
load
stabl
state
exacerb
differ
accord
exacerb
frequenc
differ
sputum
bacteri
load
frequent
infrequ
exacerb
baselin
exacerb
onset
fig
b
howev
frequent
exacerb
signific
increas
log
bacteri
load
week
post
exacerb
onset
fig
suggest
copd
subgroup
may
increas
likelihood
secondari
bacteri
infect
virusinduc
exacerb
previous
report
rhinovirusinduc
secondari
bacteri
infect
occur
neutrophil
elastasemedi
cleavag
reduct
antimicrobi
peptid
amp
slpi
elafin
process
occur
copd
healthi
subject
may
accentu
inhal
corticosteroid
use
given
observ
increas
bacteri
load
frequent
exacerb
next
examin
whether
subgroup
copd
patient
concurr
reduc
slpi
elafin
level
differ
sputum
slpi
elafin
level
frequent
infrequ
exacerb
either
baselin
supplementari
fig
exacerb
supplementari
fig
suggest
differenti
express
amp
underli
increas
secondari
bacteri
infect
frequent
exacerb
next
focus
anoth
amp
could
import
drive
secondari
bacteri
infect
copd
previou
studi
report
mannosebind
lectin
mbl
polymorph
associ
defici
serum
associ
recurr
infect
exacerb
copd
consist
report
also
found
concentr
sputum
significantli
reduc
frequent
versu
infrequ
exacerb
stabl
state
figur
also
week
post
exacerb
onset
figur
timepoint
bacteri
load
increas
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
observ
frequent
exacerb
reduc
level
increas
bacteri
load
week
post
exacerb
onset
next
examin
relationship
variabl
signific
neg
correl
sputum
concentr
bacteri
load
figur
suggest
lower
level
may
contribut
increas
secondari
bacteri
infect
frequent
exacerb
underli
mechan
involv
increas
suscept
frequent
exacerb
remain
crucial
research
question
copd
show
first
time
patient
copd
histori
frequent
exacerb
reduc
airway
antimicrobi
immun
assess
clinic
stabil
subsequ
virusassoci
exacerb
associ
increas
bacteri
load
addit
confirm
copd
frequent
exacerb
reduc
ex
vivo
immun
respons
rv
infect
primari
airway
epitheli
cell
indic
innat
antivir
defici
first
studi
show
frequent
exacerb
impair
airway
antimicrobi
respons
provid
import
mechanist
advanc
understand
clinic
import
copd
subgroup
abnorm
could
predispos
patient
greater
risk
acquisit
pathogen
virus
bacteria
andor
promot
greater
likelihood
develop
exacerb
follow
infect
influenza
infect
bec
impair
copd
patient
copd
also
increas
viru
load
enhanc
exacerb
sever
experiment
infect
rhinoviru
howev
defect
antivir
immun
shown
univers
studi
report
opposit
effect
augment
ex
vivo
antivir
respons
copd
discrep
copd
studi
suggest
defect
immun
may
present
patient
number
confound
compet
factor
diseas
sever
medic
like
influenc
plausibl
patient
frequent
exacerb
might
repres
one
subgroup
impair
antivir
immun
report
express
type
type
iii
ifn
mrna
reduc
frequent
exacerb
stabl
state
suggest
patient
might
reduc
potenti
gener
protect
respons
viru
infect
support
hypothesi
also
observ
antivir
respons
includ
isg
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
suppress
exacerb
frequent
exacerb
rvinduct
viperin
mrna
bec
ex
vivo
also
reduc
frequent
exacerb
studi
provid
first
evid
frequent
exacerb
innat
antivir
immun
dysfunct
suggest
reduct
interferon
product
might
underli
augment
propens
viru
infect
thu
increas
exacerb
frequenc
observ
patient
mechan
support
clinic
studi
report
copd
patient
frequent
exacerb
experi
significantli
coryz
episod
infrequ
exacerb
given
inhal
therapi
shown
confer
clinic
benefit
subgroup
sever
asthmat
patient
develop
cold
data
rais
suggest
innat
immuneboost
therapi
could
effect
use
target
manner
patient
copd
evid
frequent
exacerb
less
effect
innat
immun
respons
despit
observ
impair
ex
vivo
rvinduct
ifn
isg
mrna
frequent
exacerb
bec
hour
postinfect
observ
correspond
differ
protein
product
type
iii
ifn
cell
timepoint
studi
limit
sampl
avail
allow
evalu
singl
timepoint
previous
report
protein
product
ifn
persist
least
hour
cell
type
feasibl
evalu
later
timepoint
may
requir
observ
signific
differ
translat
ifn
protein
despit
lack
differ
absolut
level
ifn
protein
reduc
isg
express
observ
frequent
exacerb
support
less
effect
ifninduc
respons
subject
bacteri
infect
also
associ
exacerb
copd
increas
pcrbase
bacteri
detect
exacerb
versu
stabl
state
suggest
caus
role
addit
virusinduc
secondari
bacteri
infect
report
experiment
natur
occur
exacerb
previous
report
experiment
rv
challeng
patient
copd
associ
increas
frequenc
secondari
bacteri
infect
compar
healthi
subject
via
mechan
neutrophil
elastasemedi
cleavag
antimicrobi
peptid
slpi
elafin
extend
find
reveal
frequent
exacerb
higher
bacteri
load
week
follow
onset
virusassoci
exacerb
suggest
subgroup
copd
patient
might
greatest
risk
develop
secondari
bacteri
infect
follow
initi
viru
infect
although
found
differ
level
slpi
elafin
accord
exacerb
frequenc
identifi
express
anoth
amp
reduc
frequent
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
exacerb
stabl
state
viru
posit
exacerb
potenti
import
virusassoci
exacerb
demonstr
find
express
correl
neg
bacteri
load
exacerb
mbl
key
compon
innat
immun
activ
lectin
complement
pathway
involv
process
bacteri
phagocytosi
mbl
defici
associ
suscept
respiratori
tract
infect
pneumonia
healthi
individu
increas
risk
sepsi
anim
model
mbl
bind
variou
pathogen
relev
copd
exacerb
includ
virus
bacteria
genet
mbl
defici
previous
shown
associ
increas
reduc
exacerb
frequenc
copd
although
serum
mbl
concentr
shown
differ
frequent
infrequ
exacerb
previou
studi
report
reduc
bronchoalveolar
lavag
mbl
concentr
copd
versu
healthi
subject
data
extend
observ
demonstr
defici
airway
baselin
subsequ
exacerb
might
predispos
frequent
exacerb
increas
secondari
bacteri
infect
previou
studi
report
presenc
rhinoviru
associ
increas
spneumonia
colon
children
mbl
gene
polymorph
suggest
role
mbl
virusinduc
secondari
bacteri
infect
given
nebulis
plasmaderiv
mbl
shown
restor
phagocyt
function
smokeexpos
mice
data
rais
specul
administr
mbl
could
addit
consid
effect
prevent
andor
therapeut
strategi
copd
exacerb
studi
need
evalu
import
note
causat
infer
result
studi
although
found
reduc
antimicrobi
respons
patient
histori
frequent
exacerb
reliabl
conclud
abnorm
directli
lead
inher
increas
exacerb
risk
per
se
like
number
addit
factor
may
contribut
observ
differ
notabl
stabl
state
analys
frequent
exacerb
show
trend
toward
greater
ic
use
less
current
smoke
confound
could
contribut
directli
indirectli
differ
observ
previous
report
therefor
consid
studi
hypothesi
gener
emphasis
import
futur
larger
vivo
studi
care
dissect
influenc
variou
factor
definit
answer
question
whether
defici
antimicrobi
immun
underli
propens
exacerb
frequenc
copd
previou
studi
also
indic
exacerb
risk
copd
dynam
may
chang
year
year
longerterm
studi
repeat
airway
sampl
would
need
determin
whether
baselin
antimicrobi
respons
similarli
dynam
natur
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
conclus
show
patient
copd
histori
frequent
exacerb
reduc
antivir
antibacteri
immun
associ
increas
secondari
bacteri
infect
immun
defect
may
underli
increas
propens
exacerb
observ
subgroup
provid
evid
support
therapeut
approach
boost
innat
immun
copd
authorfund
right
reserv
reus
allow
without
permiss
tabl
baselin
characterist
patient
copd
undergo
bronchoscop
sampl
airway
epitheli
cell
experi
shown
figur
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
figur
legend
figur
copd
patient
frequent
exacerb
reduc
antivir
immun
clinic
stabil
cohort
patient
copd
monitor
prospect
sputum
sampl
taken
clinic
stabl
least
week
patient
stratifi
accord
exacerb
frequenc
preced
year
patient
experienc
exacerb
episod
classifi
frequent
sputum
cell
mrna
express
measur
quantit
pcr
b
sputum
supernat
protein
concentr
measur
elisa
sputum
cell
mrna
express
interferonstimul
gene
isg
c
viperin
measur
quantit
pcr
box
whisker
plot
show
median
line
within
box
iqr
box
minimum
maximum
whisker
statist
comparison
made
use
mann
whitney
u
test
p
ns
nonsignific
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
figur
copd
patient
frequent
exacerb
reduc
antivir
immun
virusassoci
natur
occur
exacerb
cohort
patient
copd
monitor
prospect
patient
stratifi
accord
exacerb
frequenc
preced
year
patient
experienc
exacerb
episod
classifi
frequent
sputum
sampl
taken
present
exacerb
associ
posit
viru
detect
week
exacerb
sputum
mrna
express
b
viperin
measur
quantit
pcr
sputum
protein
concentr
c
measur
elisa
data
display
box
whisker
plot
show
median
line
within
box
iqr
box
minimum
maximum
whisker
statist
comparison
made
use
mann
whitney
u
test
p
ns
nonsignific
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
figur
copd
patient
frequent
exacerb
increas
bacteri
load
viru
associ
natur
occur
exacerb
cohort
patient
copd
monitor
prospect
patient
stratifi
accord
exacerb
frequenc
preced
year
patient
experienc
exacerb
episod
classifi
frequent
sputum
sampl
taken
present
exacerb
associ
posit
viru
detect
week
exacerb
sputum
bacteri
load
measur
quantit
pcr
baselin
b
exacerb
c
week
data
shown
median
iqr
analys
mann
whitney
u
test
p
ns
nonsignific
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
iqr
box
minimum
maximum
whisker
statist
comparison
made
use
mann
whitney
u
test
c
correl
analysi
use
nonparametr
spearman
correl
p
ns
nonsignific
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
